CAJ | 학술논문

目的探讨18α甘草酸二铵脂质复合物与甘草酸二铵胶囊治疗慢性病毒性肝炎的疗效和安全性.方法慢性乙型或丙型病毒性肝炎患者55例,随机分为治疗组和对照组.治疗组给予18α甘草酸二铵脂质复合物(50 mg/粒)治疗,对照组给予甘草酸二铵胶囊(50 mg/粒)治疗;治疗剂量相同:第1～10周每次3粒,第11周每次2粒,第12周每次1粒;每日3次;停药后均随访4周.观察治疗过程中肝功能的动态变化及治疗12周时丙氨酸氨基转移酶(ALT)复常率和随访结束时的复发率.结果两组患者治疗前资料可比性良好.治疗组患者治疗4、8、12周时ALT与治疗前相比明显下降(P=0.00);而对照组仅在治疗至12周时才有明显下降(P<0.05).治疗结束时治疗组和对照组的ALT复常率分剐为38.5%和34.5%(P=0.76).组间不良反应发生率相似.结论18α甘草酸二铵脂质复合物可快速、安全地降低慢性乙、丙型病毒性肝炎患者的氨基转移酶.
목적 탐토18α감초산이안지질복합물여감초산이안효낭치료만성병독성간염적료효화안전성.방법만성을형혹병형병독성간염환자55례,수궤분위치료조화대조조.치료조급여18α감초산이안지질복합물(50 mg/립)치료,대조조급여감초산이안효낭(50 mg/립)치료;치료제량상동:제1～10주매차3립,제11주매차2립,제12주매차1립;매일3차;정약후균수방4주.관찰치료과정중간공능적동태변화급치료12주시병안산안기전이매(ALT)복상솔화수방결속시적복발솔.결과량조환자치료전자료가비성량호.치료조환자치료4、8、12주시ALT여치료전상비명현하강(P=0.00);이대조조부재치료지12주시재유명현하강(P<0.05).치료결속시치료조화대조조적ALT복상솔분과위38.5%화34.5%(P=0.76).조간불량반응발생솔상사.결론18α감초산이안지질복합물가쾌속、안전지강저만성을、병형병독성간염환자적안기전이매.
Objective To investigate the therapeutic effieacy and safety of 18 α-Diammonium glycyrrhizinate phosphatidylcholine complex (DGPC) in patients with chronic hepatitis B and or C with elevated aminotransferase. Methods 55 patients with chronic hepatitis B and or C, with serum alanine aminotransferase (ALT) of 2 to 10 times the upper limit of normal were randomly assigned to receive DGPC or Diammonium glyeyrrhizinate (DG) for 12 weeks. Then they were followed up for an additional 4 weeks. From week 1 to 10, DGPC or DG was given as 150 nag,three times a day (TID). At the 11th week,the drug was given as 100 mg,TID. Then 50 mg,TID for the 12th week. Results ALT was markedly decreased after receiving DGPC 4,8,12 weeks (P=0.00). ALT normalization rate at the end of therapy was similar (38.5% vs 34.5% ,P =0.76). Drug-related adverse events were similar. Conclusion DGPC can rapidly and safely decrease aminotransferase in patients with chronic viurs hepatitis.